I think an at-risk Copaxone launch is very unlikely without a favorable ruling from the District Court. If NVS/MNTA (and now MYL) prevail against Teva in the District Court, NVS/MNTA might decide to launch before a decision is rendered by the appellate court (assuming that they had FDA approval by then).
The 30-month Hatch-Waxman stay is now irrelevant in the Copaxone case; it will run out before the patent trial has even started.
Market Data 
Markets 
AI
